After 30 years, new drugs in AML field have been approved by FDA

[product information of chinapharma.com] recently, the US Food and Drug Administration (FDA) approved the combination of medosteurin and chemotherapy in the treatment of AML patients with ftl3 mutation The drug is a new drug approved to treat AML since 1990 Minocycline is an oral multi kinase inhibitor developed for the treatment of AML patients with ftl3 mutations The drug inhibits a variety of kinases, including ftl3, that help regulate many important cellular processes, thereby disrupting the ability of cancer cells to grow and proliferate With the wide application of molecular detection technology, many molecular markers with independent prognostic significance in acute myeloid leukemia (AML) have been detected FLT3 mutation is a common gene mutation in AML At present, FLT3 mutation is related to poor prognosis, and new therapy is urgently needed in this field In the past 25 years, the clinical treatment strategy of AML has remained unchanged It is estimated that there are 350000 leukemia patients worldwide, of which about 25% are AML One third of AML patients carry FLT3 mutations The effectiveness and safety of medetoline in the treatment of primary AML patients were reported at the 2015 American annual meeting of Hematology (ash) In this randomized 3-phase trial, 717 AML patients who had not been treated before received the treatment of metoclopramide The survival time of patients receiving the treatment of metoclopramide + chemotherapy was longer than that of patients receiving chemotherapy alone, but the median survival rate could not be estimated accurately In addition, the median event-free survival rate was 8.2 months in the group treated with mitomycin and 3 months in the group treated with chemotherapy alone Common adverse reactions associated with metoproline include febrile neutropenia, nausea, vomiting, headache, mucositis, ecchymosis, musculoskeletal pain, epistaxis, device related infection, hyperglycemia and upper respiratory tract infection Pregnant or lactating women should not use the drug because it may cause harm to the developing fetus or newborn When the patient has symptoms or pulmonary toxicity symptoms, the use of metoproline should be stopped In addition to the indication of AML with ftl3 mutation, minocycline has also been approved for the treatment of invasive systemic mastocytosis and systemic mastocytosis with hematological tumor or mast cell leukemia In these patients, the common adverse reactions of metoproline are vomiting, nausea, diarrhea, edema, musculoskeletal pain, abdominal pain, fatigue, upper respiratory tract infection, fever, headache, constipation and shortness of breath Yimaitong: FDA approvals first new drug for AML since 1990.2017